In order to investigate the relative role of central 6-and F-opioid receptors in behavior, the effects of (DAla*)cleltorphin II, a natural Gopioid peptide, and PL017, a beta-casomorphin derivative specific for mu receptors, were compared after local intracerebral and intraventricular administration. lntracerebral infusion of the two peptides was done bilaterally in the limbic nucleus accumbens and in the ventral and dorsal caudate putamen of freely moving rats through chronic intracerebral cannulas. After intra-accumbens infusion, the two peptides elicited marked but opposite behavioral effects: while (o-Ala2)deltorphin II evoked dosedependent motor stimulation characterized by locomotion, sniffing, and oral stereotypies, PLO17 elicited motor inhibition with rigidity and catalepsy. These effects were site specific because they could not be evoked from the ventral or from the dorsal caudate. Low doses of naloxone (0.1 mg/ kg, s.c.) blocked the effects of PLO17 but not those of (DAla2)deltorphin II, which instead were reduced by high doses of naloxone (1 .O mg/kg) and by the putative b-antagonist naltrindole; this drug failed to affect the catalepsy induced by PLO1 7. Therefore, while (D-Ala*)deltorphin II effects were b-mediated, PLO1 7 effects were p-mediated. Blockade of dopamine D, receptors by SCH 23390 abolished (DAla*)deltorphin II effects, while blockade of dopamine D, receptors by raclopride or by haloperidol was without effect. Local application by reverse dialysis of (D-Ala*)deltorphin II (5 PM) to the accumbens resulted in a naloxone-sensitive increase of extracellular dopamine concentrations; these effects could not be evoked from the caudate, nor by PLO17 in the accumbens. lntracerebroventricular administration of (o-Ala*)deltorphin II or of PLO17 elicited behavioral effects qualitatively similar to those obtained from the accumbens.
In order to investigate the relative role of central 6-and F-opioid receptors in behavior, the effects of (DAla*)cleltorphin II, a natural Gopioid peptide, and PL017, a beta-casomorphin derivative specific for mu receptors, were compared after local intracerebral and intraventricular administration. lntracerebral infusion of the two peptides was done bilaterally in the limbic nucleus accumbens and in the ventral and dorsal caudate putamen of freely moving rats through chronic intracerebral cannulas. After intra-accumbens infusion, the two peptides elicited marked but opposite behavioral effects: while (o-Ala2)deltorphin II evoked dosedependent motor stimulation characterized by locomotion, sniffing, and oral stereotypies, PLO17 elicited motor inhibition with rigidity and catalepsy. These effects were site specific because they could not be evoked from the ventral or from the dorsal caudate. Low doses of naloxone (0.1 mg/ kg, s.c.) blocked the effects of PLO17 but not those of (DAla2)deltorphin II, which instead were reduced by high doses of naloxone (1 .O mg/kg) and by the putative b-antagonist naltrindole; this drug failed to affect the catalepsy induced by PLO1 7. Therefore, while (D-Ala*)deltorphin II effects were b-mediated, PLO1 7 effects were p-mediated. Blockade of dopamine D, receptors by SCH 23390 abolished (DAla*)deltorphin II effects, while blockade of dopamine D, receptors by raclopride or by haloperidol was without effect. Local application by reverse dialysis of (D-Ala*)deltorphin II (5 PM) to the accumbens resulted in a naloxone-sensitive increase of extracellular dopamine concentrations; these effects could not be evoked from the caudate, nor by PLO17 in the accumbens. lntracerebroventricular administration of (o-Ala*)deltorphin II or of PLO17 elicited behavioral effects qualitatively similar to those obtained from the accumbens.
Opioids are known to influence behavior in a complex, often biphasic manner (Babbini and Davis, 1972; Domino et al., 1976; Costa11 et al., 1978; Tortella et al., 1978) . On the basis of local intracerebral administration and electrophysiological studies (Broekkamp et al., 1979; Kelley et al., 1980; Stinus et al., 1980; Matthews and German, 1984; Latimer et al., 1987) ; and, more recently, of brain dialysis studies in freely moving rats (Di Chiara and Imperato, 1988a,b; Di Chiara, 1990) , limbic dopamine (DA) has been implicated in the stimulant actions of systemic opiates. Morphine-like opiates stimulate DA release preferentially in the nucleus accumbens (Di Chiara and Imperato, 1988a) and elicit hypermotility sensitive to blockade by the DA D, receptor antagonist SCH 23390 (Longoni et al., 1987a) . Intra-accumbens infusion of opioid peptides elicits motor stimulation, but this action seems independent from DA, being resistant to classic DA-receptor antagonists (neuroleptics; Pert and Sivit, 1977; Kalivas et al., 1983) . Moreover, the syndrome elicited by intraaccumbens opiates is biphasic, as motor stimulation is typically preceded by motor inhibition and catalepsy (Costa11 et al., 1978) . This biphasic character might be due to differential behavioral properties of p-versus &receptor stimulation in the accumbens (Havemann and Kuschinsky, 1985; DaugC et al., 1988) . However, no clearcut demonstration exists for separate r/6 functions in the CNS, and some authors have even suggested that &re-ceptors cooperate with p-receptors for functional expression (Vaught and Takemori, 1979; Rothman and Westfall, 1982) . Clarification of this issue rests on the availability of potent and specific agonists of, respectively, p-and b-opioid receptors. While specific b-agonist peptides have only been known for a few years (Chang et al., 1983) , information about specific and high-intrinsic-activity &agonists had been lacking until the recent availability of (D-Ala2)deltorphin II (Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH,), a peptide extracted from the skin of a South American frog (Erspamer et al., 1989) ; with this &agonist and with PLO 17 as a specific p-agonist (Blanchard et al., 1987) , we have undertaken a study of the behavioral and biochemical effects of the selective stimulation of p-and &opioid receptors in the rat nucleus accumbens.
Materials and Methods
Animals. Male Spraque-Dawley rats (Charles River; 280-300 gm) were used. Animals were housed in groups of six under constant temperature (21°C) and humidity and a light-dark cycle of 12 hr (light at 7:OO). Food and water were available ad libitum. All experiments were performed between 8:00 and 13:O0. Surgery and injection procedure. Rats were anesthetized with Equithesin (pentobarbital, 0.8 gm; chloral hydrate, 4.25 gm; MgSO,, 2.12 gm; propylene glycol, 40 ml; alcohol 95%, 10 ml; H,O, 34 ml), placed on a David Kopf stereotaxic apparatus, and implanted bilaterally with permanent cannulas fixed to the skull using acrylic cement. Guide cannulas (22-gauge stainless steel) were positioned 2 mm above the intended injection site. Coordinates were accumbens: A, 3.4; L, 2; V, 7.2; dorsal caudate: A, 1.6; L, 3.2; V, 5 or 4; ventral caudate: A, 2.8; L, 3.5; V, 7.2; lateral ventricle: A, 0; L, 1.5; V, 3.2 (Pellegrino et al., 1979) . Stilets were inserted in the guide cannulas, and the animals were housed individually for recovery.
The drugs were injected by an infusion pump in a volume of 0.5 or 1 pl of saline at a rate of 0.5 rl/min. Intracerebroventricular injections were made bilaterally in a volume of 5 ~1 for each side. After infusion, the cannulas were kept in place for additional 2 min to allow diffusion of the drugs.
Behavioral testing. Two days after surgery, each rat was placed in a Perspex cage (27 x 42 x 15 cm) with a steel grid on the bottom and habituated for 60 min. The bottoms of the cages were divided into four equal sectors. After the habituation period and while in the same cage, each animal was given a subcutaneous injection of saline or of drugs 15 min (naloxone, SCH 23390, raclopride, naltrindole) or 2 hr (haloperidol) before bilateral intracerebral or intracerebroventricular injection. Behavior was videotaped, and the following behavioral categories were distinguished: 1, horizontal locomotion associated with sniffing; 2, rearing; 3, confined sniffing; 4, licking of the floor; 5, biting of the floor (gnawing); 6, grooming. When rats showed immobility with frozen postures, they were tested for catalepsy by placing them on a vertical wire grid, an animal was considered cataleptic if it remained immobile on the grid for more than 20 sec. Locomotion was measured by counting the number of sectors entered by the rat with its forelegs. Rearing and grooming were measured in terms of number of items observed during periods of 10 min. The other behavioral items were quantified in terms of percentage of time spent by the rat in performing each behavior during each IO-min period. The behavior ofeach rat was observed continuously for 90 min after the intracerebral administration, and on videotapes only one behavioral item was analyzed at one time. Rats were used only once.
Dialysis. The rats were implanted under halothane anesthesia with a dialysis tube (AN-69 Hospal; 0.3-mm outer diameter) inserted trans- versally through the dorsal caudate (coordinates: A, 7.4; V, 5.5), or MA). (D-Ala2)deitorphin II was obtained as previously reported (Erthrough the nucleus accumbens (coordinates: A, 9.6; V, 7.0; Konig and spamer et al., 1989) . All drugs were dissolved in saline. Haloperidol Klippel, 1963) . solution (Serenase, Janssen) was diluted in distilled water. The technique used to prepare and implant the dialysis probes was essentially that already described (Imperato and Di Chiara, 1984 . Experiments were performed in freely moving rats 24 hr after surgery. The Ringer's solution used for perfusing the dialysis fibers had the following composition: 147 mM NaCl, 2.2 mM CaCl,, and 4.0 mM KCl. Samples (20 mitt, 40 ~1) of dialysate were injected in a highperformance liquid chromatograph equipped with a reverse-phase ODS column (Supelcosil, Supelco Inc., Bellefonte, PA) and with an electrochemical detector (BAS, Lafayette, IN) in order to quantitate DA, dihydroxyphenylacetic (DOPAC), and homovanillic acid (HVA), according to the procedure already reported (Imperato and Di Chiara, 1984) .
Statistics. The data were analyzed by one-way ANOVA for repeated measures followed by Newman-Keuls multiple comparison test. Differences were considered as significant at p < 0.05.
Results
Histology. After behavioral testing, rats were given an overdose of Equithesin and perfused intracardially with saline followed by 10% formalin: the brains were removed, frozen, and sectioned in order to determine the locations of the cannulas (Fig. 1) .
DIWS. The followina drugs were used:
The bilateral intra-accumbens administration of (DAlaz)deltorphin II (0.5-2.0 kg on each side) elicited a syndrome of pure behavioral stimulation characterized by locomotion (typically associated with sniffing), by rearing and grooming, and by stereotyped behavior with confined sniffing, gnawing, and licking (Fig. 2) . The incidence of these behavioral items was dose related. Ala-Phe-Glu-Val-Val-Gly-l?Hz), SCH 23390 (kindly donated by Dr. E. Ongini, Essex, Italy), raclopride (ASTRA Lakemedel AB, Sodertalje, Sweden), PLO 17 (Peninsula Laboratories, CA), naloxone hydrochloride (Sigma Chemical Co., St. Louis, MO), and naltrindole (RBI, Natick, Locomotion increased after all the doses tested (0.5, 1, and 2.0 pg, bilaterally); rearing and stereotypies (confined sniffing and licking/gnawing) reached a plateau at 1 .O and 2.0 pg; con- fined sniffing occupied the first half of the time course, while oral stereotypies (licking and gnawing) occupied the second half. Increasing the dose from 1 to 2 pg resulted in a shift from lower-(confined sniffing) to higher-intensity sterotypies (licking/gnawing).
As shown in Figure 3 and Table 1 , rather high doses of naloxone (1 mg/kg, s.c.) were necessary to prevent the effects of 1 or 2 pg (D-Ala*)deltorphin II; lower doses of naloxone (0.1 mg/ kg, s.c.) were ineffective. Naltrindole (6 mg/kg, s.c.), a reportedly selective centrally acting nonpeptide d-antagonist (Portoghese et al., 1988) , significantly reduced the deltorphin syndrome (Table  1, Fig. 3 ). The behavioral syndrome induced by intra-accumbens (D-Ala2)deltorphin II (1 or 2 pg, bilaterally) was prevented by low doses ofthe potent antagonist of D, receptors SCH 23390 (0.025 and 0.05 mg/kg, s.c.; Fig. 4 Table 1 ).
Intracaudate (o-Ala2)deltorphin II As shown in Table 2 , infusion of 0.5-2.0 rg (o-Ala*)deltorphin II in the dorsal or in the ventral caudate elicited behavioral effects not different from saline.
Intra-accumbens PLO1 7
In contrast with the &agonist (D-Ala2)deltorphin II, the selective peptidic r-agonist PLO17 (0. l-l pg), infused bilaterally in the accumbens, elicited a syndrome of motor inhibition with rigidity and catalepsy whose duration was dependent from the dose administered (Fig. 5 ). The catalepsy was phenomenologically similar to neuroleptic catalepsy rather than to typical lead-pipe rigidity (see Di Chiara et al., 1979) . No motor stimulation was observed during the 2 hr of observation. Naloxone, in low doses (0.1 mg/kg, s.c.), reversed the catalepsy induced by intra-accumbens PLO17 (0.5 cLg bilaterally; Fig. 6 ). In contrast, the putative s-antagonist naltrindole (6 mg/kg, s.c.) failed to attenuate significantly the catalepsy elicited by 0.5 cLg PLO17 in the accumbens (Fig. 6 ).
Intracaudate PLO1 7 PLO 17 (0.5 Fg) infused in the dorsal caudate induced only mild and short-lasting catalepsy and rigidity (not shown).
Intracerebroventricular (o-Ala-')deltorphin II and PLO1 7
Opioids are known to exert biphasic effects after systemic or intracerebral administration (see introductory remarks). In order to evaluate the significance of the effects evoked by the peptides from the accumbens in terms of their overall central effects, we studied the behavioral effects of (D-Ala2)deltorphin II and of PLO 17 after intracerebroventricular administration. Intracerebroventricular (D-Ala2)deltorphin II (10 Mg; Fig. 7 ) elicited within minutes a dose-related motor activation qualitatively similar to but less intense than that obtained after intraaccumbens infusion of the same compound. Stereotyped items (confined sniffing, licking/gnawing) were present also after doses of 5 pg bilaterally. Intracerebroventricular (D-Ala*)deltorphin II-induced stereotypy was prevented by subcutaneous doses of naloxone as high as 1 .O mg/kg (Fig. 7) ; lower doses (0.1 mg/kg) were ineffective (not shown). The D, antagonist SCH 23390 (0.05 mg/kg, s.c.) completely prevented the behavioral stimulation and the stereotypies elicited by intracerebroventricular (D-AlaZ)deltorphin II (Fig. 7) . Intracerebroventricular PLO 17 (5 wg) elicited a catalepsy syndrome indistinguishable from that elicited by this compound after intra-accumbens infusion (Fig. 8) . Low doses of systemic naloxone (0.1 mg/kg, KC.) prevented intracerebroventricular PLO 17-induced catalepsy (Fig. 8) .
the arousing effects of the manipulations involved in the local injection procedure.
Brain dialysis
In freely moving rats implanted with dialysis probes in the accumbens, (D-AlaZ)deltorphin II, added to the Ringer's solution, stimulated DA release in a concentration-dependent manner (threshold, 5 PM; maximal, 50 PM; maximum increase over basal, + 120%; Fig. 9A ). During the application of the highest concentration of (D-Ala2)deltorphin II (50 PM), a syndrome of motor stimulation was observed similar to that evoked by intraaccumbens injection of the same compound.
Intra-accumbens and intracaudate saline
No changes in DA release and behavior were observed after As shown in Table 2 , intra-accumbens or intracaudate saline reverse dialysis of D-Ala2)deltorphin II in the dorsal caudate resulted only in mild, short-lasting motor activation related to (Fig. 9B) . Systemic administration of naloxone (1 mg/kg, s.c.) prevented the stimulation of DA output and motor activity evoked by dialysis with 50 PM (D-Ala2)deltorphin II in the accumbens (Fig.  10) . Intra-accumbens dialysis of PLO 17 (50 PM) failed to modify the output of DA and of its metabolites (Fig. 1lA) in spite of it's ability to induce catalepsy. Intra-caudate dialysis of PLO17 (50 WM) was ineffective on DA output and on behavior (Fig.  11B ).
Discussion
(D-Ala2)deltorphin II is a highly specific and potent agonist of &opioid receptors (Erspamer et al., 1989) . Thus, in binding studies, (D-Ala*)deltorphin II has been found to have an affinity for d-receptors at least 3000 times higher that for p-receptors; in the same experiments, D-Pen, D-Pen enkephalin was about 10 times less selective (Erspamer et al., 1989) . On isolated organs, (D-Ala2)deltorphin II showed a potency in eliciting &ac-tions at least 10,000 times higher than that required for evoking M-actions (Erspamer et al., 1989) . PL017, on the other hand, shows quite high selectivity and potency for p-receptors (Blanchard et al., 1987 ). An additional characteristic of these compounds is their metabolic stability, which derives from the presence of a strategically placed D-amino acid in the peptide chain (Chang et al., 1976 (Chang et al., , 1983 .
The present study demonstrates intense (stereotyped), topographically discrete (restricted to the accumbens), and receptorspecific motor stimulation after intracerebral infusion of (D-Ala2)deltorphin II. Sterotypies similar to those elicited by intra-accumbens (D-Ala2)deltorphin II and characterized by confined sniffing, licking, and gnawing are typically obtained by stimulation of dopaminergic receptors (Longoni et al., 1987b) . The motor stimulation previously reported after intra-accumbens infusion of nonspecific opioid peptides such as (D-Ala*-DLeu5)enkephalin (DADLE; Pert and Sivit, 1977; Kalivas et al., 1983) was characterized by locomotor stimulation without stereotypy and therefore appears mild in comparison with that observed in the present study after (D-Ala*)deltorphin II. This might be due in part to residual activity of DADLE at p-receptors, whose stimulation, by inhibiting motor activity (see below), might have prevented the full expression of the behavioral stimulant effect of b-receptor stimulation. This suggestion is supported by the fact that the locomotor stimulation induced by intra-accumbens DADLE is generally preceded by catalepsy, which is likely to be a p-effect (see below).
The sensitivity of (D-Ala2)deltorphin II effects to blockade by naltrindole (Portoghese et al., 1988) and by 1 .O but not by 0.1 mg/kg naloxone is consistent with its 6 nature (Yoshimura et al., 1982) .
The motor-stimulant effects of intra-accumbens (DAla2)deltorphin II, like those of DADLE (Pert and Sivit, 1977; Kalivas et al., 1983) , were not significantly reduced by haloperidol; in contrast, SCH 23390, a specific D, antagonist (Hyttel, 1983) , completely prevented the entire behavioral syndrome induced by intra-accumbens (D-Ala*)deltorphin II. If one considers that haloperidol is a preferential D, antagonist (Seeman, 1980) , the most parsimonious explanation of the differential effect of SCH 23390 and haloperidol on (D-Ala2)deltorphin II effects is that they are mediated by DA acting specifically on D, receptors. In agreement with this, the present study shows that raclopride, a specific D, antagonist (Ogren et al., 1986) , fails to modify the deltorphin syndrome. On the other hand, our study also shows that intra-accumbens dialysis of (D-Ala2)deltorphin II stimulates DA release in the accumbens. Stimulation of DA release by intra-accumbens (D-Ala2)deltorphin II might take place through presynaptic stimulatory &receptors; it is puzzling, however, that such receptors have been shown in the caudate but not in the accumbens (Lubetzki et al., 1982; Petit et al., 1986) . Deltorphin-induced behavioral stimulation appears mediated specifically by D, receptors in the accumbens. Indeed, the motor effects of (D-Ala2)deltorphin II are not the only example of a mesolimbic DA-mediated response showing preferential blockade by the D, antagonist SCH 23390. In fact, high sensitivity to SCH 23390 is also observed for the motor-stimulant effects of systemic morphine (Longoni et al., 1987a; Pollock and Kornetsky, 1989) . One explanation of these findings is that in the mesolimbic DA system the true synaptic receptor for DA is the D, receptor, while D, receptors might be nonsynaptic receptors activated by excess DA released from nerve terminals or by exogenous D, agonists. An alternative explanation would be that The results obtained with intra-accumbens (D-Ala2)deltorphin II suggest a revision of the concept that opioids exert DA-dependent behavioral stimulation from the ventral tegmentum and DA-independent stimulation from the nucleus accumbens (Kalivas et al., 1983 ). This conclusion was based on the differential sensitivity to haloperidol of the effects of intrategmental as compared to intra-accumbens DADLE. By analogy with (DAla2)deltorphin II, we now suggest that the stimulant effects of intra-accumbens DADLE are also dopaminergic but are me- diated by D, receptors. Studies are in progress in order to confirm this suggestion.
Intra-accumbens or intracerebroventricular infusion of the k-opioid peptide PLO 17 resulted in a behavioral syndrome quite opposite to that evoked by (D-Ala2)deltorphin II. Thus, PLO17 evoked a syndrome of motor inhibition and catalepsy sensitive to low doses of naloxone (0.1 mg/kg, s.c.) but not to naltrindole; this syndrome was reminiscent of the catalepsy elicited by neuroleptics (DA receptor blockers) rather than of the lead-pipe catalepsy elicited by systemic morphine-like opiates (see Di Chiara et al., 1979 , for discussion of this issue). However, apart from this apparent relationship with DA, local application of PLO 17 by accumbens dialysis failed to modify DA release, indicating that the behavioral effects of PLO 17 are not due to a presynaptic interference with DA transmission, but eventually to a modulatory action of p-receptors on the effects of stimulation of postsynaptic DA receptors. In fact, recent results show that stimulation of p-receptors reduces the stimulatory action of D, receptor activation on CAMP production (Groppetti et al., 1990) .
The observation of clearcut differential effects of b-versus p-receptor stimulation in the accumbens provides strong behavioral and biochemical evidence for separate functions of pand b-receptors in specific brain areas. In the accumbens, a morphological substrate of such differential behavioral effects might be the differential distribution of opioid receptors, as demonstrated by receptor autoradiography; this distribution is diffuse for 6-and patchy for b-receptors (Mansour et al., 1988) .
The accumbens appears to be a specific site of origin of the central motor effects of CL-or 6-opioid receptor stimulation, because no motor effects were obtained from dorsal or ventral caudate administration of PLO 17 or (D-Ala2)deltorphin II. Indeed, the lack of responses from the caudate is surprising in view of the fact that this area contains high concentrations of p-as well as &receptors and that the presence of &receptors stimulating DA release has been shown in this area rather than in accumbens (Lubetzki et al., 1982) . Failure to obtain behavioral responses after intracaudate administration of opioid peptides might be due to the fact that the area to be influenced for obtaining an effect is larger than that which can be reached by diffusion by relatively polar compounds such as the peptides. Alternatively, the responsive area in the caudate is quite small, and we simply failed to hit the right spot (Kelley et al., 1988) .
If indeed, as indicated by the present study, the motor-stimulant effects of intra-accumbens opioid peptides are mediated by &receptors, it is unlikely that the motor-stimulant effects of systemic morphine-like opiates, which are mu in nature, are due to a direct action on the accumbens as suggested by Amalric and Koob (1985) . In fact, as shown by the results obtained in the present study with PL017, an action of morphine in the accumbens would rather result in catalepsy. The motor-stimulant effects of systemic morphine are more likely to be due to stimulation of p-receptors in the ventral tegmentum area (VTA)-medial substantia nigra (SN), resulting in disinhibition of DA neurons projecting to the accumbens (Di Chiara and Imperato, 1988b; Morelli et al., 1989) . It is interesting, therefore, that while both p-and d-opioids can stimulate DA transmission in the mesolimbic DA system and produce behavioral activation, the mechanism of these effects is different for the two types of opioid receptors, taking place proximally (i.e., in the SN-VTA region) in the case of M-opiates and distally (i.e., in limbic terminal DA regions) in the case of d-opioids.
The present results are in contrast with the notion that oral stereotypies arise from the caudate rather than from the accumbens (Creese and Iversen, 1975) ; indeed, this conclusion derives from studies performed with amphetamine, whose effects, in contrast with those of (D-Ala')deltorphin II, are blocked not only by D, but also by D, antagonists (Creese and Iversen, 1975) . The differential sensitivity of amphetamine and (DAla*)deltorphin II to D, antagonism indicates that the population of DA receptors stimulated by amphetamine is different from that stimulated following intra-accumbens deltorphin. This in turn might be the basis for the ability of (D-Ala2)deltorphin II, in contrast with amphetamine, to elicit oral stereotypies from the accumbens. In this respect, it is notable that (DAla2)deltorphin II is capable of eliciting D,-dependent oral stereotypies even under strong blockade of D, receptors by raclopride or by haloperidol. This would imply that, under &re-ceptor stimulation, concurrent D, and D, stimulation (Longoni et al., 1987b) is not essential for the expression of oral stereotypies. A reason for this might be that delta-receptor stimulation strongly potentiates the effect of D, receptor stimulation by DA released by deltorphin.
The observation of the present study that &receptors exert a powerful facilitatory influence on dopaminergic transmission in the accumbens might have far-reaching consequences. In fact, the mesolimbic dopamine system (which includes as a major terminal area the accumbens) is currently regarded as an interface for the conversion of motivation into action (Mogenson et al., 1980) . In particular, stimulation of DA transmission is regarded as a major factor in the rewarding properties of various stimuli, including natural reinforcers (food, sex) and drugs of abuse (Wise and Rompre, 1989) ; &receptors, on the other hand, have been shown to exert DA-dependent rewarding effects (Shippenberg et al., 1987) . Given these premises, an interaction like the one reported in the present study might provide a possible neurochemical basis for the postulated role of the limbic system in normal and abnormal behavior (Stevens, 1973) . To summarize, a number of conclusions can be drawn from the present study. First, d-receptors in the accumbens exert a powerful stimulant influence on DA transmission consisting of stimulation of DA release and resulting in typical stereotyped behavior.
Second, p-receptors in the accumbens elicit a powerful inhib- itory influence on motor activity (catalepsy), which appears independent from changes in DA release. Therefore, at least for motor behavior, the actions of p-and &receptor stimulation can be clearly separated; this shows that the two receptors can be distinguished not only at the recognition site but also at the behavioral level. Third, the motor stimulant effects of intra-accumbens (DAla2)deltorphin II are specifically mediated by D, receptors. Because these effects appear to be due to a stimulation of DA release in the accumbens, the results suggest that D, rather than D, receptors are the synaptic receptors for DA in the accumbens or, alternatively, that stimulation of &receptor specifically potentiates D, responses. Finally, as shown by the similarity of the effects of intracerebroventricular and intra-accumbens (DAla2)deltorphin II and PLO 17, the accumbens is among the most influential sites for the motor effects of 6-and p-opioids in the forebrain, and this role can be clearly distinguished from that of the caudate.
